ArticleScientific reports2026

Trabectedin plus CD13-targeted tissue factor tTF-NGR against advanced relapsed or refractory soft tissue sarcoma: translational data, clinical safety and efficacy.

Kathrin Hessling et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.